INmune Bio (INMB) Competitors

INmune Bio (NASDAQ:INMB) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Is INMB or CDMO more profitable?

INmune Bio has a net margin of 0.00% compared to Avid Bioservices' net margin of -101.07%. Avid Bioservices' return on equity of -33.18% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-117.48%	-78.96%
Avid Bioservices	-101.07%	-33.18%	-8.45%

Does the MarketBeat Community believe in INMB or CDMO?

Avid Bioservices received 226 more outperform votes than INmune Bio when rated by MarketBeat users. However, 76.60% of users gave INmune Bio an outperform vote while only 65.95% of users gave Avid Bioservices an outperform vote.

Company	Underperform	Outperform
INmune Bio	Outperform Votes 144 76.60%	Underperform Votes 44 23.40%
Avid Bioservices	Outperform Votes 370 65.95%	Underperform Votes 191 34.05%

Do institutionals & insiders have more ownership in INMB or CDMO?

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 97.2% of Avid Bioservices shares are held by institutional investors. 35.2% of INmune Bio shares are held by company insiders. Comparatively, 3.1% of Avid Bioservices shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has stronger valuation and earnings, INMB or CDMO?

INmune Bio has higher earnings, but lower revenue than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$42K	4,534.70	-$30.01M	-$2.18	-3.94
Avid Bioservices	$139.91M	5.71	-$140.75M	-$2.39	-5.23

Does the media prefer INMB or CDMO?

In the previous week, INmune Bio had 4 more articles in the media than Avid Bioservices. MarketBeat recorded 5 mentions for INmune Bio and 1 mentions for Avid Bioservices. INmune Bio's average media sentiment score of 1.00 beat Avid Bioservices' score of 0.10 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avid Bioservices	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer INMB or CDMO?

INmune Bio currently has a consensus target price of $22.80, suggesting a potential upside of 165.42%. Avid Bioservices has a consensus target price of $12.25, suggesting a potential downside of 1.96%. Given INmune Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe INmune Bio is more favorable than Avid Bioservices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Avid Bioservices	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more risk and volatility, INMB or CDMO?

INmune Bio has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Summary

INmune Bio beats Avid Bioservices on 14 of the 19 factors compared between the two stocks.